CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

Anecortave

Trade name: retaane

Small moleculeexperimental

Anecortave (rINN) is a novel angiogenesis inhibitor used in the treatment of the exudative (wet) form of age-related macular degeneration. Although similar in chemical structure to the corticosteroid hydrocortisone acetate, it possesses no glucocorticoid activity. If it is approved, it will be marketed by Alcon as anecortave acetate for depot suspension under the trade name Retaane. No development has been reported since 2010. — Wikipedia

Clinical trial activity

32 trials · 7 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
24
Phase 3
10
Phase 4
0

Earliest trial started Apr 1, 1999 (NCT00346957)

Timeline

1990s

  1. Jan 1, 1999

    Earliest Phase 2 Sponsor(trial)

2000s

  1. Jan 1, 2002

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2005

    Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

  • Unspecified targetOTHER

    Unknown

    Molecular mechanism not well known. Deacetylated in ocular tissue to the active metabolite anecortave desacetate. Functions as an antiangiogenic agent, inhibiting blood vessel growth by decreasing extracellular protease expression and inhibiting endothelial cell migration. Angiostatic activity does not seem to be mediated through any of the commonly known pharmacological receptors. Blocks signals from multiple growth factors, acting downstream and independent of initiating angiogenic stimuli.

Chemistry & pharmacology

Loading structure…

SMILES

CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@@]21C
Mol. weight
386.49 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 4,9(11)-pregnadien-17alpha,21-diol-3,20-dione-21-acetate
  • al 3789
  • al-3789
  • al-3789
  • al-3789
  • al-3789
  • anecortave
  • anecortave
  • anecortave
  • anecortave
  • anecortave
  • anecortave acetate
  • anecortave acetate
  • anecortave acetate
  • anecortave acetate
  • anecortave acetate
  • anecortave acetate
  • anecortave acetate
  • retaane

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00884039N/AMay 1, 2009Cornea Research Foundation of America
NCT00788541Phase 2Dec 1, 2008Alcon
NCT00691717Phase 2/Phase 3 (Phase 3)Jun 1, 2008Alcon
NCT00705770Phase 2/Phase 3 (Phase 3)May 1, 2008Alcon
NCT00211432Phase 2Apr 1, 2008Alcon, Manhattan Eye, Ear & Throat Hospital
NCT00643669Phase 2Feb 1, 2008Alcon
NCT00533962N/AAug 1, 2007Alcon, University of Sao Paulo
NCT00489840Phase 1/Phase 2 (Phase 2)May 1, 2007Alcon, LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear & Throat Hospital
NCT00451152Phase 2Mar 1, 2007Alcon
NCT00051129Phase 3Jan 1, 2007Alcon
NCT00332657Phase 3Sep 1, 2006Alcon
NCT00570479Phase 1Sep 1, 2006Alcon, Texas Retina Associates
NCT00320203Phase 2Mar 1, 2006Alcon
NCT00315640Phase 2Dec 1, 2005Alcon
NCT00211406Phase 1Sep 13, 2005Alcon, Manhattan Eye, Ear & Throat Hospital
NCT00211419Phase 1Sep 13, 2005Alcon, Manhattan Eye, Ear & Throat Hospital
NCT00211458Phase 2Sep 1, 2005Alcon, Manhattan Eye, Ear & Throat Hospital
NCT00333216Phase 3May 1, 2005Alcon
NCT00299507Phase 3Mar 1, 2005Alcon
NCT00211367Phase 2Apr 1, 2004Alcon, Manhattan Eye, Ear & Throat Hospital
Showing 20 of 32 trials
Page 1 / 2

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AlconFor profit301741999
Manhattan Eye, Ear & Throat HospitalAcademic/Hospital111122002
Cornea Research Foundation of AmericaAcademic/Hospital1112009
LuEsther T. Mertz Retinal Research CenterAcademic/Hospital1012007
Texas Retina AssociatesAcademic/Hospital1112006
University of IowaAcademic/Hospital1112003
University of Sao PauloAcademic/Hospital1112007
7 organizations
Page 1 / 1